Black seed compound joins fight against inoperable liver cancer
NCT ID NCT06217094
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This early-stage study aimed to find the safest dose of NP-101, a drug made from black seed, when given alongside standard radiation therapy (Y-90) for people with liver cancer that cannot be surgically removed. The goal was to see if NP-101 could boost the immune system to improve treatment results. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.